Migraine Diagnosis and Treatment
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine -
The In¯Uence of Medication on Erectile Function
International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted. -
Headache in Primary Care *
HeadacHe IN PRIMARY CARE * Dr Neil Whittaker - GP, Nelson Key Advisers: Dr Alistair Dunn - GP, Whangarei Dr Alan Wright - Neurologist, Dunedin Expert Reviewer: Every headache presentation is unique and challenging, requiring a flexible and individualised approach to headache management. - Most headaches are benign primary headaches - A few headaches are secondary to underlying pathology, which may be life threatening Primary headaches can be difficult to diagnose and manage. People, who experience severe or recurrent primary headache, can be subject to significant social, financial and disability burden. We cannot cover all the issues associated with headache presentation in primary care; instead, our focus is on assisting clinicians to: - Recognise presentations of secondary headaches - Effectively diagnose primary headaches - Manage primary headaches, in particular tension-type headache, migraine and cluster headache - Avoid, recognise and manage medication overuse headache 10 I BPJ I Issue 7 www.bpac.org.nz keyword: “Headache” DIAGNOSIS OF HEADACHE IN PRIMARY CARE The keys to headache diagnosis in primary care are: - Ensuring occasional presentations of secondary headache do not escape notice - Differentiating between the causes of primary headache - Addressing patient concerns about serious pathology RECOGNISE SERIOUS SECONDARY HEADACHES BY BEING ALERT FOR RED FLAGS AND PERFORMING FUNDOSCOPY Although primary care clinicians worry about Red Flags in headache presentation missing serious secondary headaches, most Red Flags in headache presentation include: people presenting with secondary headache will have alerting clinical features. These Age clinical features, red flags, are not highly - Over 50 years at onset of new headache specific but do alert clinicians to the need for - Under 10 years at onset particular care in the history, examination and Characteristics investigation. -
Deprescribing Anticholinergic and Sedative Medicines: Protocol for a Feasibility Trial (DEFEAT- Polypharmacy) in Residential Aged Care Facilities
Open Access Protocol BMJ Open: first published as 10.1136/bmjopen-2016-013800 on 16 April 2017. Downloaded from Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT- polypharmacy) in residential aged care facilities Nagham Ailabouni,1 Dee Mangin,2 Prasad S Nishtala1 To cite: Ailabouni N, ABSTRACT Strengths and limitations of this study Mangin D, Nishtala PS. Introduction: Targeted deprescribing of Deprescribing anticholinergic anticholinergic and sedative medicines can lead to ▪ and sedative medicines: Using a quantitative measure (ie, the Drug Burden positive health outcomes in older people; as they have protocol for a Feasibility Trial Index) will help to determine the effect of depre- (DEFEAT-polypharmacy) in been associated with cognitive and physical scribing anticholinergic and sedative medicines. residential aged care facilities. functioning decline. This study will examine whether ▪ A pharmacist conducting in-depth medicine BMJ Open 2017;7:e013800. the proposed intervention is feasible at reducing the reviews could help to alleviate time constraints doi:10.1136/bmjopen-2016- prescription of anticholinergic and sedative medicines often faced by general practitioners in the resi- 013800 in older people. dential care setting. Methods and analysis: The Standard Protocol ▪ Six months may not be adequate to fully investi- ▸ Prepublication history and Items: Recommendations for Interventional trials gate the clinical effects of deprescribing. additional material is (SPIRIT checklist) was used to develop and report the available. To view please visit protocol. Single group (precomparison and the journal (http://dx.doi.org/ postcomparison) feasibility study design. 10.1136/bmjopen-2016- Study population: 3 residential care homes have INTRODUCTION 013800). been recruited. -
Antimigraine Agents, Triptans Review 07/21/2008
Antimigraine Agents, Triptans Review 07/21/2008 Copyright © 2004 - 2008 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended -
Frovatriptan Versus Zolmitriptan for the Acute Treatment of Migraine: a Double-Blind, Randomized, Multicenter, Italian Study
Neurol Sci (2010) 31 (Suppl 1):S51–S54 DOI 10.1007/s10072-010-0273-x SYMPOSIUM: NEWS IN TREATMENT OF MIGRAINE ATTACK Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study Vincenzo Tullo • Gianni Allais • Michel D. Ferrari • Marcella Curone • Eliana Mea • Stefano Omboni • Chiara Benedetto • Dario Zava • Gennaro Bussone Ó The Author(s) 2010. This article is published with open access at Springerlink.com Abstract The objective of this study is to assess patients’ of PF episodes at 2 h was 26% with F and 31% with Z satisfaction with migraine treatment with frovatriptan (F) (p = NS). PR episodes at 2 h were 57% for F and 58% for or zolmitriptan (Z), by preference questionnaire. 133 sub- Z(p = NS). Rate of recurrence was 21 (F) and 24% jects with a history of migraine with or without aura (IHS (Z; p = NS). Time to recurrence within 48 h was better for criteria) were randomized to F 2.5 mg or Z 2.5 mg. The F especially between 4 and 16 h (p \ 0.05). SPF episodes study had a multicenter, randomized, double-blind, cross- were 18 (F) versus 22% (Z; p = NS). Drug-related adverse over design, with each of the two treatment periods lasting events were significantly (p \ 0.05) less under F (3 vs. 10). no more than 3 months. At the end of the study, patients In conclusion, our study suggests that F has a similar were asked to assign preference to one of the treatments efficacy of Z, with some advantage as regards tolerability (primary endpoint). -
Preventive Report Appendix
Title Authors Published Journal Volume Issue Pages DOI Final Status Exclusion Reason Nasal sumatriptan is effective in treatment of migraine attacks in children: A Ahonen K.; Hamalainen ML.; Rantala H.; 2004 Neurology 62 6 883-7 10.1212/01.wnl.0000115105.05966.a7 Deemed irrelevant in initial screening Seasonal variation in migraine. Alstadhaug KB.; Salvesen R.; Bekkelund SI. Cephalalgia : an 2005 international journal 25 10 811-6 10.1111/j.1468-2982.2005.01018.x Deemed irrelevant in initial screening Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Amery WK. 1983 Headache 23 2 70-4 10.1111/j.1526-4610.1983.hed2302070 Deemed irrelevant in initial screening Monoamine oxidase inhibitors in the control of migraine. Anthony M.; Lance JW. Proceedings of the 1970 Australian 7 45-7 Deemed irrelevant in initial screening Prostaglandins and prostaglandin receptor antagonism in migraine. Antonova M. 2013 Danish medical 60 5 B4635 Deemed irrelevant in initial screening Divalproex extended-release in adolescent migraine prophylaxis: results of a Apostol G.; Cady RK.; Laforet GA.; Robieson randomized, double-blind, placebo-controlled study. WZ.; Olson E.; Abi-Saab WM.; Saltarelli M. 2008 Headache 48 7 1012-25 10.1111/j.1526-4610.2008.01081.x Deemed irrelevant in initial screening Divalproex sodium extended-release for the prophylaxis of migraine headache in Apostol G.; Lewis DW.; Laforet GA.; adolescents: results of a stand-alone, long-term open-label safety study. Robieson WZ.; Fugate JM.; Abi-Saab WM.; 2009 Headache 49 1 45-53 10.1111/j.1526-4610.2008.01279.x Deemed irrelevant in initial screening Safety and tolerability of divalproex sodium extended-release in the prophylaxis of Apostol G.; Pakalnis A.; Laforet GA.; migraine headaches: results of an open-label extension trial in adolescents. -
Triptans Step Therapy/Quantity Limit Criteria
Triptans Step Therapy/Quantity Limit Criteria Program may be implemented with the following options 1) step therapy 2) quantity limits or 3) step therapy with quantity limits For Blue Cross and Blue Shield of Illinois Option 1 (step therapy only) will apply. Brand Generic Dosage Form Amerge® naratriptan tablets Axert® almotriptan tablets Frova® frovatriptan tablets Imitrex® sumatriptan injection*, nasal spray, tablets* Maxalt® rizatriptan tablets Maxalt-MLT® rizatriptan tablets Relpax® eletriptan tablets Treximet™ sumatriptan and naproxen tablets Zomig® zolmitriptan tablets, nasal spray Zomig-ZMT® zolmitriptan tablets * generic available and included as target agent in quantity limit edit FDA APPROVED INDICATIONS1-7 The following information is taken from individual drug prescribing information and is provided here as background information only. Not all FDA-approved indications may be considered medically necessary. All criteria are found in the section “Prior Authorization Criteria for Approval.” Amerge® Tablets1, Axert® Tablets2, Frova® Tablets3,Imitrex® injection4, Imitrex Nasal Spray5, Imitrex Tablets6, Maxalt® Tablets7, Maxalt-MLT® Tablets7, Relpax® Tablets8, Treximet™ Tablets9, Zomig® Tablets10, Zomig-ZMT® Tablets10, and Zomig® Nasal Spray11 Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan), Maxalt (rizatriptan), Maxalt-MLT (rizatriptan orally disintegrating), Relpax (eletriptan), Treximet (sumatriptan/naproxen), Zomig (zolmitriptan), and Zomig-ZMT (zolmitriptan orally disintegrating) tablets, and Imitrex (sumatriptan) and Zomig (zolmitriptan) nasal spray are all indicated for the acute treatment of migraine attacks with or without aura in adults. They are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of all of these products have not been established for cluster headache, which is present in an older, predominantly male population. -
Zomig and Zomig Rapimelt Are Trade Marks of the Astrazeneca Group of Companies
AUSTRALIAN PRODUCT INFORMATION Zomig® and Zomig Rapimelt® (zolmitriptan) 1 NAME OF THE MEDICINE Zolmitriptan 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Zomig is presented as round, yellow (2.5 mg) or pink (5 mg), biconvex film-coated intagliated (with a ‘Z’ on one side) tablets containing 2.5 mg or 5 mg zolmitriptan. The 2.5 mg tablets are 7.4 mm in diameter and are compressed to a weight of 122 mg. The 5 mg tablets are 8.6 mm in diameter and are compressed to a weight of 244 mg. Zomig Rapimelt is presented as orally dispersible white round uncoated orange flavoured tablets containing 2.5 mg zolmitriptan. The tablets are 6.4 mm in diameter, flat-faced with a bevelled edge and intagliated with ‘Z’ on one side. The tablets are compressed to a weight of 100 mg. Excipient(s) with known effect: lactose monohydrate (Zomig), aspartame (Zomig Rapimelt). For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM • Tablet, film-coated • Tablet, dispersible (oral) 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zomig is indicated for the acute treatment of migraine with or without aura. 4.2 DOSE AND METHOD OF ADMINISTRATION The recommended initial dose of Zomig to treat a migraine attack is 2.5 mg. The Zomig conventional tablet should be swallowed whole with water. The Zomig Rapimelt orally dispersible tablet rapidly dissolves when placed on the tongue and is swallowed with the patient’s saliva. A drink of water is not required when taking the Zomig Rapimelt orally dispersible tablet. -
A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache
University of South Florida Masthead Logo Scholar Commons School of Information Faculty Publications School of Information 7-2015 A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache Authors: Jeffrey L. Jackson, Elizabeth Cogbill, Rafael Santana-Davila, Christina Eldredge, William Collier, Andrew Gradall, Neha Sehgal, and Jessica Kuester OBJECTIVE: To compare the effectiveness and side effects of migraine prophylactic medications. DESIGN: We performed a network meta-analysis. Data were extracted independently in duplicate and quality was assessed using both the JADAD and Cochrane Risk of Bias instruments. Data were pooled and network meta-analysis performed using random effects models. DATA SOURCES: PUBMED, EMBASE, Cochrane Trial Registry, bibliography of retrieved articles through 18 May 2014. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We included randomized controlled trials of adults with migraine headaches of at least 4 weeks in duration. RESULTS: Placebo controlled trials included alpha blockers (n = 9), angiotensin converting enzyme inhibitors (n = 3), angiotensin receptor blockers (n = 3), anticonvulsants (n = 32), beta-blockers (n = 39), calcium channel blockers (n = 12), flunarizine (n = 7), serotonin reuptake inhibitors (n = 6), serotonin norepinephrine reuptake inhibitors (n = 1) serotonin agonists (n = 9) and tricyclic antidepressants (n = 11). In addition there were 53 trials comparing different drugs. Drugs with at least 3 trials that were more effective than placebo for episodic migraines -
Zolmitriptan Intranasal Spanlastics for Enhanced Migraine Treatment; Formulation Parameters Optimized Via Quality by Design Approach
Scientia Pharmaceutica Article Zolmitriptan Intranasal Spanlastics for Enhanced Migraine Treatment; Formulation Parameters Optimized via Quality by Design Approach Asmaa Saleh 1, Maha Khalifa 2 , Seham Shawky 2, Amjaad Bani-Ali 3 and Heba Eassa 2,* 1 Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia; [email protected] 2 Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo 11651, Egypt; [email protected] (M.K.); [email protected] (S.S.) 3 Pharmacy Practice Department, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia; [email protected] * Correspondence: [email protected]; Tel.: +20-114-261-2925 Abstract: Zolmitriptan is a potent second-generation triptan prescribed for migraine attacks. It suffers low bioavailability (40%) after oral administration due to the hepatic first-pass metabolism. Spanlastics are surfactant-based elastic vesicular drug carrier systems. This study aimed to design and optimize intranasal spanlastic formulations as an alternative approach that directly targets brain delivery, enhancing its bioavailability and avoiding the first-pass effect. The quality by design approach was applied to correlate the formulation parameters (Span 60 and Tween 80 concentrations) and critical quality attributes (entrapment efficiency (EE%) and particle size). Spanlastic formulations Citation: Saleh, A.; Khalifa, M.; were designed based on response surface central composite design and prepared via an ethanol injec- Shawky, S.; Bani-Ali, A.; Eassa, H. tion method. Designed formulations were characterized by EE% and particle size measurements to Zolmitriptan Intranasal Spanlastics select the optimized formula (with a combination of small particle size and high EE%). -
RELPAX® (Eletriptan Hydrobromide) Tablets
RELPAX® (eletriptan hydrobromide) Tablets DESCRIPTION RELPAX® (eletriptan) Tablets contain eletriptan hydrobromide, which is a selective 5 hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist. Eletriptan is chemically designated as (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H indole monohydrobromide, and it has the following chemical structure: CH OO OO 3 N S . HBr N H The empirical formula is C22H26N2O2S . HBr, representing a molecular weight of 463.40. Eletriptan hydrobromide is a white to light pale colored powder that is readily soluble in water. Each RELPAX Tablet for oral administration contains 24.2 or 48.5 mg of eletriptan hydrobromide equivalent to 20 mg or 40 mg of eletriptan, respectively. Each tablet also contains the inactive ingredients microcrystalline cellulose NF, lactose NF, croscarmellose sodium NF, magnesium stearate NF, titanium dioxide USP, hypromellose, triacetin USP and FD&C Yellow No. 6 aluminum lake. CLINICAL PHARMACOLOGY Mechanism of Action: Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. Eletriptan has no significant affinity or pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. Two theories have been proposed to explain the efficacy of 5-HT receptor agonists in migraine. One theory suggests that activation of 5-HT1 receptors located on intracranial blood vessels, including those on the arteriovenous anastomoses, leads to vasoconstriction, which is correlated with the relief of migraine headache.